AMERICAN Journal of Pediatric Medicine and Health Sciences
Volume 4, Issue 5, 2026 ISSN (E): 2993-2149

Overview of Antimicrobial Resistance: Patterns, Drivers, and Strategic Responses to a Growing Public Health Threat

Mayyadah Ali Ahmed Al-Gburi[1]
[1] Baiji Primary Health Care Sector, Salah al-Din Health Directorate
lymyadh326@gmail.com

Ghada Nasrat Khalaf[2]
[2] Al-Doura Primary Health Care Sector, Baghdad Health Directorate/Al-Karkh
ghadankhalaf@gmail.com

Khaldoon Bataal Ahmed[3]
[3] Dep. of Biology, College of Education for Pure Sciences, University of Anbar, Iraq
mtckhaldoon2007@gmail.com

Abdulsalam Abdulsattar Abdulazez[4]
[4] Dep. of Microbiology, Faculty of Medical Sciences, Çankırı University, Türkiye
alhetysalam@gmail.com

Abstract: Antibiotic resistance act as a crucial fast-growing medical threat to worldwide health, which erases medical achievements from past decades. Antibiotic resistance occurs because bacteria develop protective mechanisms that disable antibiotic treatments, which subsequently results in premature disease fatalities. Each year antibiotic resistance causes more deaths than HIV/AIDS and malaria combined because it results in 1.27 million worldwide fatalities from resistant infections. Antibiotic-resistant pathogens contribute to more than 2.8 million annual infections together with 35,000 yearly deaths across the United States as well as other nations with high income. The article delivers an extensive analysis of antibiotic resistance worldwide, which includes information about regional patterns and root causes together with key bacterial species. Comprehensive knowledge about the depth and intricacy of resistance as a global health issue enables similar worldwide efforts to reduce resistance while safeguarding public health and maintaining the effectiveness of present and future antimicrobial drugs. In the end, urgent global collaboration is essential to reverse this alarming trend.

Keywords: Antibiotic resistance, Global resistance, WHO, bacteria.

Introduction

Antibiotic resistance is one of the most significant challenges facing human health today, representing the ability of bacteria to survive the use of antibiotics. Alarming data support the World Health Organization's (WHO) classification of this phenomenon as one of the most serious threats to human health [1]. The total deaths from antibiotic use across the world exceeds infectious diseases including HIV/AIDS and malaria because antibiotics lead to 1.27 million deaths annually. Hamdulay and colleagues reported in 2024 that antibiotic-resistant infections will affect more than 2.8 million people in the United States and these infections will cause greater than 35,000 deaths [2]. International antibiotic resistance movements have generated widespread worry about the upcoming "post-antibiotic era" which features common bacterial infections immune to current antibiotic therapies. A rapid spread of Colistin-resistant *E. coli* was reported from Chinese cattle into both European and US territories within a few months according to Tiong et al [3]. Multiple elements cause this issue with antibiotic use being particularly important for human and animal medicine. The worldwide livestock antibiotic consumption totaled 130 thousand tons in 2013 and experts predict this amount will increase to 240 thousand tons by 2030, which represents a projected growth in antibiotic resistance [4][5]. Bacteria with heightened drug resistance patterns produce crucial effects on health services for humans and animals [6]. The increased resistance of bacteria to drugs affects heavily on both human and animal medical conditions. The techniques force researchers to go beyond statistical observation to study how resistance emerges and spreads as well as develop solutions for dealing with it [7]; this method shows potential for solving one of the major health challenges we face today.

This review investigates antibiotic resistance worldwide through mortality rate and financial cost assessment as well as bacterial resistance species identification and antibiotic distribution patterns. This study delivers global antimicrobial resistance challenges to create better scientific backing for new strategies that stop antimicrobial resistance from expanding.

Methodology

This study is designed as a systematic narrative review aimed at synthesising global evidence on AMR following its patterns, drivers and strategic responses. MethodologyThe study is based primarily on a document review of various peer-reviewed scientific papers, international health organization reports, and surveillance databases (such as those provided by the World Health Organization [WHO] and global monitoring systems like GLASS). Methods A systematic literature search was performed in major academic databases (PubMed, Scopus, and Google Scholar) for studies on antimicrobial resistance trends, mortality rates, economic impacts, geographical distributions, and resistance mechanisms of bacteria published until October 2023. Articles from wide-ranging topics but with older studies and dated statistics were excluded in order to retain validated data on resistance prevalence, antibiotic consumption and public health perspectives via accepted and disapproved sources. These data consisted of statistical indicators including resistance rates, mortality rates, consumption of antibiotics, or geographical distribution, as well as descriptive information like impacts from misuse of antibiotics, animal husbandry, or weaknesses in health systems. The descriptive synthesis of the analytical approach with critical content analysis aimed to identify patterns, relationships, and discrepancies in regions and pathogens. Comparisons were also made to assess differences in resistance burden and health capacity between high-income countries and low- and middle-income countries. This cross-disciplinary approach allows for a comprehensive insight into AMR as a complex global health threat and support the evaluation of evidence behind current visualizations and inform top-down, multidisciplinary strategies to tackle the increasing burden of AMR.

1. Global mortality and economic impact

Antimicrobial resistance (AMR) is a massive global health threat whose mortality burden continues to increase. A recent analysis of death data suggests that direct bacterial AMR directly resulted in approximately 1.27 million deaths globally in 2019, followed by 2.95 million of these deaths due to AMR-related complications [7][8]. The level of mortality already exceeds that of the main global diseases such as HIV/AIDS and malaria. Indeed, sub-Saharan Africa has at least 27. Three deaths per 100000 persons due to AMR [9].

If current trends were supported, according to projections, the projected number of deaths due to AMR/emergency would be an utterly catastrophic 10 million annually by 2050 [10][11]. The estimated geographic distribution shows that approximately 4 million deaths per year of this estimated number would be experienced in Asia and Africa, which are determined to have disproportionate effects on low and middle-income countries [12]. The WHO has described this as such a critical situation that, in 2011, they used the phrase "No action today, no cure tomorrow" to signal a very urgent need for a coordinated global response.

The economic impact of AMR is equally alarming. Current estimates suggest that the cumulative global economic losses associated with uncontrolled AMR are projected to reach USD 100 trillion by 2050. These economic losses are principally due to increased morbidity and mortality linked to treatment failures, infections during medical procedures, and overall reduced quality of life [13]. Improperly disproportionate burden is attributed to developing countries, where healthcare infrastructure is very scarce [14]. The dramatically increasing antibiotic use worldwide (31, 32), has been one of the main drivers of this crisis. In low and middle-income countries, however, between 2000 and 2015, there was a 77% increase in antibiotic use and a 114% increase in total overall utilization (Pattnaik et al., 2023). Apprehension over escorting consumption is given the current high amount of dimension of the total consumption of antibiotics considered unnecessary [15][16].

Lately, the matter started to find its way into the sphere of veterinary medicine, targeting the areas of agricultural practices, and of course, medical treatment for humans. The year 2013 observed the administration of 130,000 tons of antimicrobials to food animals. The 2030 estimates predict that this amount will be over 200,000 tons [17]. The employment of these drugs in the agricultural sector stands out as the main source of the increased resistance levels to antimicrobials via indirect exposure to environmental mechanisms [18][19][20].

Due to the severity of this situation around the world, several international organizations, one of them being the United Nations recognized antimicrobial resistance (AMR) as the major global health threat which needs to be deal with quickly, together and in a coordinated way [21][22]. The absence of substantial action will pose a threat to the world, as not only will AMR but also it will become a real obstacle to the progress that the medical field has had over the years and even drag us back to an era of deadly infections [23].

2. Regional variations in resistance rates

Antibiotics resistance rates have been observing a good deal of diversity around the world, with significant differences between rich countries and LMICs (low and middle-income countries) being the main problem. The global resistance rate is ascending, but typically, LMICs happen to have higher resistance levels while they consume fewer antibiotics [24]. This phenomenon results in a situation where the most affected by bacterial diseases countries have the least antecedents useful, meaning that their access to newer and more effective antibiotics has been reduced.

According to the World Health Organization's (WHO)conducted surveillance, data and reporting of drug resistance are quite varied in different regions, with Europe as the region with the most extensive set of data(74% coverage) while the Eastern Mediterranean barely reaches up to 32%. In contrast to varying reporting intensities, the WHO data do still reveal resistance levels among pathogens that have significantly exceeded 50% in many regions, most notably for bacteria such as *E. coli*, K. pneumoniae, and *S. aureus* [25]. Of the investigated countries, Carbapenem resistance showed the most outrageous increase in more than 75% of the countries [26]. Worryingly, the data over the period have portrayed that the H. pylori resistance in treatment of naïve patients in Europe has been constantly increasing. The clarithromycin resistance, for example, remained over 15% throughout 2013-2020, which is still higher than the threshold that allows guidelines to recommend using clarithromycin-based regimens. The improvement in the case of metronidazole was from 33% to 24% during the periods of 2013-2016 and 2017-2020, which was a very significant reduction, while tetracycline and amoxicillin remain with overall <1% resistance [27].

The World Health Organization (WHO) has been writing in their official publication about an approaching crisis in Asia caused by the resistance of the microorganisms as the situation is "particularly worrisome" in this geographical area due to the different factors like antibiotic 'overuse, limited infection control, waste mismanagement, antibiotic consumption in animal husbandry, lack of access to the latest antibiotics [28][29][30]. investigation located Africa and Asia as the two regions of the world where the highest number of multi-drug resistant S. aureus from blood infections were isolated [31]. From place to place, the number of cases of Methicillin-resistant S. aureus (MRSA) differs, and in a significant part of the cases in Asia (46.6%), north America (37.7%) and Latin America (34.2%) [31].

One of the obstacles in the control of infection in Middle Eastern countries is the high prevalence of drug-resistant bacteria, particularly Gram-negative bacteria. Resistance patterns in the whole Middle East region and the countries such as as Saudi Arabia, Egypt, Libya, Syria, and Lebanon, which have reported a serious level of resistance, especially in the case of critical care settings, are seen at a very great range [32]. A new analysis of the WHO surveillance data has suggested that Iran and Uganda are the countries that have the highest levels of daily use of antimicrobials [33].

Even more concerning is the direct relationship between antimicrobial use and resistance rates. Per rise in defined daily dose of beta- lactam/cephalosporin and quinolone, there are 11-22% more resistant *E. coli* and *Klebsiella* species causing bloodstream infections, and 31-40% more quinolone resistant strains [34], and this is interesting. European countries with a higher income follow the predicted positive correlation between consumption and resistance, whereas, the blurring of all world data gives the false impression of a weak negative correlation, which represents availability and consequently more consumption leading to resistance [35].

While resistance to nitrofurantoin and amikacin is still lower at about 14%, Mexico reports notably high resistance to ampicillin (92.5%) and trimethoprim-sulfamethoxazole (70.1%) in urinary tract pathogens [36]. These regional differences also apply to foodborne pathogens; according to recent surveillance data, *Salmonella* isolates from poultry in the US and Brazil have increasing resistance rates, while those in Canada are declining [37]. The Eastern Mediterranean region exhibits notably high antimicrobial resistance rates, with clarithromycin resistance reaching approximately 33% in *Helicobacter pylori*, significantly higher than the 10% reported in the Americas and Southeast Asia [38].

Metronidazole resistance emerges with greater frequency across the Western Pacific and Eastern Mediterranean regions according to Shatila et al. 2022. The average clarithromycin resistance rate in Africa reaches 29 yet shows significant variation between different countries. 2% [39]. Examining regional disparities becomes evident when observing Congo's minimal performance at level 1. Clarithromycin resistance stands at 7% according to Ngoyi et al. 2015 and Lin et al. 2023.

Table 1: General percentage distributions of resistance to some antibiotics by geographic region

Region	Antibiotics	Resistance rate	Comparison-Observations	Ref
Southern Europe (2021)	Clarithromycin and Levofloxacin	28% and 23.5% respectively	Northern Europe: Where rates were less than 10% for both antibiotics.	[40]
Asia 2006-2015)	clarithromycin, metronidazole, levofloxacin, azithromycin and clarithromycin	20%, 47%, and 21%, 32.2%, 30.8%, respectively	Considerably higher than rates observed in Europe	[41]
Oceania	Erythromycin,	31.5%, 0.4%, 0.1%,	Oceania	[42]

	penicillin teicoplanin, ampicillin, and vancomycin	0.1%, and 0.1%, respectively	shows much lower resistance rates than Asia.	
Americas 2011-2021	clarithromycin, levofloxacin and metronidazole amoxicillin tetracycline, ,rifabutin, clarithromycin, and metronidazole	30%, 31.5%,37.6, 42.1%, 2.6%, 0.87%, 0.17%, 11.7%, and 11.7% respectively	The proportions vary greatly depending on the antibiotics.	[43]

The Middle East displays distinct and unusual resistance patterns. H. bacteria develop complex resistance against amoxicillin. Scientific reports indicate that the occurrence rate of pylori stands at twenty-eight. In Iran a 6% rate exists which surpasses the global average [44]. An investigation from Iraq conducted within the regional context showed alarmingly high resistance rates to piperacillin (92%), ticarcillin (91%), and amoxicillin/clavulanic acid (88%) even though amikacin and imipenem resistance remained low at 11% and 5%. **In Table 1**, we briefly explain the most resistant antibiotics according to their geographical areas of use.

Antimicrobial resistance is very different across Africa and the Middle East. This makes it important to have plans for managing antibiotic use that fit each region or country. Many places face their own challenges, such as poor systems for monitoring, inadequate healthcare facilities, and varying rules about antibiotics. Because of these differences, it's clear we need solutions that target the specific causes of antibiotic resistance in each area [45].

3. Resistance patterns by bacteria type

According to WHO information, the median resistance rate to third-generation cephalosporin in 76 countries is at 42%, which is a clear signal that the use of standard antibiotics will soon be no longer effective in treating urinary tract infections. [46] For each DDD of beta-lactam/cephalosporin use increase, the resistance of bloodstream. The rate of *E. coli* resistance to such drugs raises by 11-22%, and for quinolones, resistance increases by 31-40%. [47]. See **Table 2.**

Klebsiella pneumoniae pathogen has developed a significant resistance to a variety of antibiotics such as third-generational cephalosporin, thus leading the medical society to utilize more carbapenems. [48]. *K. pneumoniae* with resistance to carbapenem has a median rate of 6.3%, which is a common problem in the world, but it varies per region a lot, e.g., more than 50% of the European and Mediterranean patients can get sick. [49].

S. aureus (MRSA) remains a significant global threat with a median resistance rate of 35% across 76 countries. [50] Most WHO regions report MRSA proportions exceeding 20%, with some regions reporting rates higher than 80%. [51].

Very worrying fact about this pathogenic microorganism is the resistance patterns it displays, with carbapenem-resistant *A. baumannii hitting* a 72.3% median rate worldwide in 2019, which is the highest of all bacteria pathogens under surveillance. The interquartile range for this resistance is up to 50.2%, which means there is significant variation between the countries. [52]

Extended-spectrum beta-lactamase-producing *Enterobacter ales* (ESBL-PE): These are considered especially problematic since over 60% of antimicrobials used worldwide are beta-lactams. [53][54] Environmental spillover from hospitals and communities contributes significantly to their spread. [55][56][57].

WHO surveillance has *Streptococcus pneumoniae*, documented non-susceptibility to penicillin across all WHO regions, contributing to the growing challenge of treating common respiratory infections. [58]

Neisseria gonorrhoeae, which is primarily responsible for the spread of sexually transmitted infections, has been noted to acquire lower susceptibility to third-generation cephalosporin. This particularly raises concern since these antibiotics are often the last recourse of treatment. The non-typhoid *Salmonella* and *Shigella* species have developed significant resistance to fluoroquinolones, thus making treatment of foodborne and waterborne illnesses more complicated. [59].

The infection cases due to MDR and XDR, especially the ones that are connected to the gram-negative bacteria, can be healed only through the most robust actions for the return of the pre-antibiotic period. [60]. The level of knowledge on the resistance rate of these pathogens remains limited due to significant geographic disparities in the collection of surveillance data. The European region contributes the most extensive information on resistance patterns (74% coverage), while the Eastern Mediterranean region is the least informed (32%) [61]. The absence of a continuous monitoring system in these regions, in conjunction with the extent of these waning efforts, only makes the management of targeted activities harder in the face of all bacterial threats. See **Table 2.**

Table 2: A list showing studies that addressed antibiotic resistance by geographic region and target bacteria.

Organisms	Region of study	Antibiotic studied	Ref.
Helicobacter pylori	All WHO regions, including Americas, South-East Asia, Europe.	Clarithromycin, metronidazole, levofloxacin, amoxicillin, tetracycline.	[62]
Helicobacter pylori	United States	Clarithromycin, amoxicillin, metronidazole, tetracycline, rifabutin, levofloxacin	[63]
Helicobacter pylori	Europe	The specific antibiotics included in the study for resistance testing were clarithromycin, metronidazole, levofloxacin, amoxicillin, and tetracycline.	[64]
Haemophilus spp.	Eight countries across North America, Asia, and Europe.	Azithromycin, erythromycin, and clarithromycin	[65]
Klebsiella pneumoniae, Acinetobacter baumannii, Escherichia coli, Streptococcus pneumoniae, Enterococci.	51 countries worldwide.	Carbapenems, fluoroquinolones, penicillin.	[66]
Klebsiella pneumoniae	Brazil	Colistin, tigecycline, amikacin, and fosfomycin	[67]

4. Drivers of antibiotic resistance

Instances of antibiotic resistance are due to a confluence of a multitude of factors that work at the individual, community, and global levels. The knowledge of these drivers is essential in the development of effective intervention strategies. The prescribing of drugs badly and the unnecessary consumption of antibiotics are undoubtedly the primary direct sources of resistant strains. Numerous studies have demonstrated a causal relationship between the global use of antibiotics and the incidence of resistance cases, with the latter being particularly severe in southern European countries, where the correlations are the highest [68].

It can be observed that antibiotics are sold without any strict regulations in various countries of the world, which is most common in some countries, especially in the low and middle-income ones. The availability of antibiotics without prescriptions makes people practice self-medication by using them. Thereby, the situation leads to a significant overuse of these drugs. [69][70].

Farm animals worldwide have experienced massive growth in their consumption of antimicrobials products such as antibiotics because BRICS countries (Brazil, Russia, India, China, and South Africa) have seen their food animal antimicrobial use surge by 180 percent. A recent study indicates agricultural antimicrobial use will expand because food production will rise from 50-70 percent between 2010 and 2030. Healthcare settings can spread resistant organisms between patients and through healthcare environments when infection prevention and control maintenance remain poor. Medical facility exposure acts as an alerting factor that leads to antibiotic resistance development, according to Sharma et al. (2024). Global consumption of carbapenems and polymyxins, two antibiotic classes considered "last resort" treatments, has been rising in both human and veterinary medicine, and further threatens their continued efficacy.

Rhizophilia, antibiotic-resistant bacteria and resistance genes develop into environmental reservoirs due to hospital waste and community waste and farming waste. The transfer of resistance determinants occurs mostly in wastewater treatment facilities and on farms, which function as hotspots for such transfer. New studies indicate a relationship between PM2.5 air pollution and growing antibiotic resistance, which provides medical professionals with an alternative method to control resistance as an extension of antimicrobial stewardship. The spread of resistant microorganisms mainly affecting LMICs occurs because residents lack access to clean water sanitation and hygiene infrastructure.

WHO data reported that monitored countries use antibiotics at a level that ranges by sixteen times. High-income countries possess greater access to last-resort antibiotic treatments but lower-income countries experience restricted access to recent antibiotic medications even though they exhibit higher resistance to treatment. Different regions deal with distinct obstacles, which boost the development of resistance. The region of Asia experiences concerning antibiotic resistance levels because of several determining factors including antibiotic overuse diagnoses and a lack of infection control protocols and proper waste disposal systems as well as agricultural antibiotic application and constrained access to new antibiotic treatments.

5. Surveillance and monitoring efforts

The monitoring of antimicrobial resistance (AMR) serves as an essential element in fighting this worldwide threat because the World Health Organization (WHO) directs global surveillance operations. WHO issued its first Global Report on Surveillance in 2014 to compile national antibacterial resistance surveillance information. The report received responses from 129 member states while 114 states reported nine bacteria-antimicrobial resistance combinations. GLASS developed from this original work to integrate antibacterial resistance data together with drug usage reports in its yearly publications.

Even with these progressions surveillance data collection continues to be distributed irregularly worldwide. The European regional surveillance reports 74% of reported surveillance data whereas the Eastern Mediterranean region reports only 32%. Surveillance data from Americas stands at

60% while the West Pacific reaches 70% and South-East Asia along with Africa report 55% and 49% respectively. The wide variation in reporting systems produces major gaps in information according to WHO analysis, which shows that "(testing of 30 isolates) the minimum data requirements are met by countries representing less than half of the global population when combining different bacterial species with antibiotic testings."

Researchers have created statistical methods to estimate antimicrobial resistance prevalence rates in nations which lack proper surveillance data. Beta-binomial principal component regression models allow scientists to determine clinical AMR prevalence using socioeconomic data. This predictive method demonstrates solid reliability when assessing most priority bacteria strains (q^2 exceeds 0.78 in tests of six out of nine bacteria) while achieving a global coverage rate of 87% that reached 99% of worldwide residents. The estimation methods can help 2.1 to 4.9 billion people within countries, which lack sufficient diagnostic facilities.

The addition of antimicrobial consumption (AMC) data to resistance monitoring systems represents one of the modern improvements in surveillance programs. The 2015 WHO consumption report showed significant differences in antibiotic use because 65 surveyed nations had antibiotic usage rates that differed by 16 times. The report documented that "access" antibiotics (which treat first and second-line diseases) made up most of the treated population within different countries, although "watch" antibiotics (showing greater resistance possibilities) ranged between 20-50% of total medication usage. High-income countries accounted for almost all reports of antibiotics designated for emergency purposes, which doctors use only as a final treatment option.

Recent GLASS data analyses confirmed that beta-lactam/cephalosporin and fluoroquinolone antibiotic consumption levels demonstrated statistically quantifiable relationships to bloodstream infection resistance rates. Scientific reports show that every DDD metric rise of these antibiotics leads to a resistant *E. coli* and *Klebsiella* species increase of 11-22% for beta-lactams/cephalosporins and a corresponding 31-40% growth for quinolone-resistant strains.

International cooperation regarding surveillance initiatives became necessary because of global recognition of antibiotic resistance as an escalating challenge. The European Centre for Disease Prevention and Control (ECDC) and the Transatlantic Taskforce on Antimicrobial Resistance together with other organizations act as global responses to combat antimicrobial resistance on a worldwide scale. Safety protocols for this resistance monitoring have become increasingly important because high-risk bacterial clones emerge internationally to rapidly spread.

Multiple strategic initiatives operate across the Americas to tackle current health concerns. Through its leadership, PAHO leads the initiative against antibiotic overutilization particularly when used in Latin American agricultural settings. The government of Chile undertook a collaborative initiative with PAHO to develop a National AMR Strategy, which aims at controlling antibiotics in agriculture and implementing hospital-based infection control protocols.

6. Low and middle-income countries' challenges

Medical resistance from antimicrobial substances threatens low and middle-income countries (LMICs) most severely causing a worldwide health inequality that worsens current healthcare differences. The World Health Organization declared this crisis a worldwide public health emergency because resource-poor settings suffer most from limited access to alternative antibiotics and high levels of multidrug-resistant bacterial strains.

The resistance rates in LMICs remain higher although these nations use fewer antibiotics than high-income countries according to Collignon et al.. The unique situation means nations that experience extensive bacterial disease pressure face limited access to superior antimicrobial treatments, which stems from their low availability of new and effective antibiotic medications. Global antibiotic consumption reveals a weak negative correlation pattern with resistance rates according to research findings yet high-income European nations exhibit a positive correlation pattern between antibiotic use and resistance.

Between 2000 and 2015, LMICs experienced significant changes in antimicrobial use when their antimicrobial consumption rates grew 77% while the total amount of antimicrobials used increased 114%. The healthcare system of LMICs faces dual challenges of ineffective diagnostics and inadequate infection prevention alongside poor waste management and restricted access to contemporary antibiotics, according to Zhang et al. (2020) and Chereau et al. (2017) and Kakkar et al. (2018).

High levels of difficulties persist within distinct geographical regions. Asia is facing "particularly alarming" enhancement of resistance according to WHO evaluations. Critical care units of Saudi Arabia, Egypt, Libya, Syria, and Lebanon show elevated multidrug-resistant infection rates, especially against Gram-negative bacteria, according to Bourgi et al (2024) and Al-Orphaly et al (2021). The AMR-related deaths in Sub-Saharan Africa reach 27.3 fatalities for each 100,000 persons, suggesting a substantial burden.

Developing countries, which have minimal healthcare facilities, bear the substantial economic burden from anti-microbial resistance (LLM Memory). Three key drivers of antimicrobial resistance in these areas consist of the public's self-treatment behavior when antibiotics can be bought without prescriptions, insufficient water and sanitation services and intensifying agricultural usage of antimicrobial drugs

The real problem arises from limited access to essential antimicrobial medications. WHO data showed antibiotic usage in 65 countries varied by 16 times but high-income nations used reserve drugs alone while LMICs faced higher antibiotic resistance burden. Countries requiring effective antimicrobials the most receive the smallest access to these critical drugs.

National Action Plans exist throughout numerous countries to fight antimicrobial resistance yet LMICs experience continuing substantial pitfalls. The insufficient collection of resistance data exists as a crucial data problem in South and Southeast Asia combined with sub-Saharan Africa where resistance shows the highest growth rate. Research shows that the death rates from AMR-related illnesses will rise to 4 million per year both in Africa and Asia by 2050 based on current patterns which demonstrates an unbalanced effect on LMICs. Among theseregions, vulnerable newborns together with their infant counterparts and expectant mothers endure the highest amounts of this healthcare burden.

6. Result and future projection

National governance improvements stand as a foundational strategy to prevent resistance, according to scientific evidence. National governance improvements lead to better healthcare practices through improved antibiotic supervision, along with distinct strategies to manage food production and water quality, and agricultural antibiotic control. The institutional approach insists that antibiotic resistance extends past medical boundaries to require comprehensive systemic changes according to Collignon et al.. Research indicates that failure to implement effective preventive measures together with control methods will result in substantial increases of resistant infections while leading to higher mortality rates, which threatens antibiotic effectiveness in future generations.

New evidence has created multiple promising opportunities for healthcare intervention, which go beyond regular antibiotic management. Research now reveals a link between PM2.5 air pollution and antibiotic resistance; thus, pollution control could become an unorthodox yet effective method to decrease worldwide resistance trends. The global antimicrobial resistance fight may obtain a supplementary weapon through air pollution management beyond essential antibiotic regulation and improved drinking water systems.

Antibiotic resistance globally has gained rising worldwide acceptance, which led countries to develop initiatives like the Transatlantic Taskforce on Antimicrobial Resistance between the United States and European Union. These international organizations have developed partnerships to understand the global movement of antibiotic resistance because New Delhi metallo-β-lactamase (NDM) and other spreading resistance mechanisms move to different countries rapidly. High-risk clones require global coordination since they exhibit long-term survivability along with their ability to acquire resistance mechanisms now of emergence and spread.

The widespread recognition about resistance control issues fails to generate enough implementation of proper control methods. The creation of National Action Plans (NAPs) exists around the world but implementation levels differ substantially between countries especially those in low and middle-income categories. Antibiotic-resistant bacteria and resistance genes remain concentrated in key resistance spread locations such as farms and hospitals and wastewater treatment plants and agricultural spaces.

Worldwide patients continue to use the antibiotic class's carbapenems and polymyxins as their primary treatment option leading to increasing consumption statistics particularly in developing regions. The worldwide use of antibiotics in agriculture exceeds human antibiotic consumption because of which new transmission pathways for the development of drug-resistant infections have emerged. The grim prospect of a world without antibiotics has surfaced due to the present circumstances, which emphasizes the necessity for better intervention methods.

Multiple international initiatives struggle against antimicrobial resistance as part of coordinated efforts because this problem requires unified action. The World Health Organization (WHO) initiated the Global Action Plan on Antimicrobial Resistance in 2015 to combat antimicrobial resistance through programs focusing on awareness enhancement and prevention implementation and resource optimization for new treatment development and responsible antibiotic use and research improvement. The plan extends what Jim O'Neill presented in his "Review on Antimicrobial Resistance" from 2014 with its strategic framework of innovation alongside international governance and technological progress and funding for sanitation and health facilities.

Clusters of small and medium-sized enterprises failed to replace pharmaceutical giants after facing financial difficulties for which the AMR Action Fund emerged as a new initiative. Multiple organizations including the pharmaceutical industry and WHO and the European Investment Bank along with the Wellcome Trust work together to invest $1 billion for developing two to four new antibiotics that patients will receive by 2030. The formation of public-private partnerships establishes itself as a vital approach to handle the leadership failures, which blocked antibiotic development.

Increased global awareness now prioritize the "One Health" strategy because it recognizes strong interconnections between humans, their animals and their environmental surroundings. All disciplines need to work together through a multidisciplinary framework to tackle antibiotic resistance since it affects medical care along with veterinary practices and environmental systems. The One Health approach now matches the United Nations' 17 Sustainable Development Goals (SDGs) because it integrates antimicrobial resistance strategies with systemic global development goals.

Antimicrobial stewardship programs (ASPs) function as essential global tools that enhance correct prescription practices to preserve both modern and forthcoming antibiotic effectiveness. The antibiotic treatment strategies work together with combination therapies, which use compatible substances with antibiotics to simultaneously improve drug effectiveness and minimize resistance formation. Governments now employ tax benefits as well as long-term purchase agreements and simplified regulatory systems, which drive pharmaceutical businesses to support antibiotic research development.

Studies confirm that developing new medications is necessary but insufficient to end the antibiotic resistance emergency. The introduction of Gram-negative antibiotics would result in preventing 11.08 million cumulative AMR deaths during the timeframe from 2025 and 2050. The same period will result in greater lifesaving potential when healthcare systems receive better access to existing antibiotics according to Naghavi et al. New pharmaceutical innovation needs balancing with enhanced healthcare infrastructure and better access to drugs in order to address antibiotic resistance effectively.

Public awareness together with health literacy serve as fundamental components for every local and global action strategy. Worldwide understanding of antibiotic resistance mechanisms has succeeded in motivating people to approach antibiotic use through both scientific and rational means. The future development of national antibiotic resistance solutions depends on the continued public education efforts which combined with awareness creation will enable healthcare providers together with pharmaceutical companies and the public to work collectively.

According to experts, the resolution of antimicrobial resistance demands flexible multiple-strategic approaches, which unite various sectors alongside multiple stakeholders. The solutions require more than healthcare industry contribution because antimicrobial efficacy needs to be treated as an essential global public benefit that is rapidly decreasing. The fight against antimicrobial resistance depends on uniting nature with technological advancements because innovative partnerships between stakeholders will build healthier communities and resistance against diseases.

7. Conclusion

Modern medicine exists with human health and economic stability at great danger because of the quick-growing worldwide antibiotic resistance problem. The review reports concerning mortality rates from drug-resistant infections and verifies that financial stress affects all economic zones alongside the global practice of inappropriate antibiotic management. The review identifies *Escherichia coli*, *Klebsiella pneumoniae* along with *Staphylococcus aureus* as important bacterial pathogens showing dangerous resistance patterns since they represent major public health threats. The elimination of antimicrobial resistance needs international authority collaborations to establish monitoring networks and manage antibiotic distribution effectively and to create hospital-grade antimicrobial substances and targeted regional interventions. Human life becomes endangered with the approach of a post-antibiotic era that could reintroduce deadly infections because of insufficient urgent measures.

References

[1] M. A. Adefisoye and A. O. Olaniran, “Antimicrobial resistance expansion in pathogens: A review of current mitigation strategies and advances towards innovative therapy,” *JAC-Antimicrobial Resistance*, vol. 5, no. 6, p. dlad127, 2023.

[2] I. Ahmad *et al.*, “Insights into *Haemophilus* macrolide resistance: A comprehensive systematic review and meta-analysis,” *PLOS Neglected Tropical Diseases*, vol. 19, no. 3, p. e0012878, 2025.

[3] S. Ajulo and B. Awosile, “Global antimicrobial resistance and use surveillance system (GLASS 2022): Investigating the relationship between antimicrobial resistance and antimicrobial consumption data,” *PLoS One*, vol. 19, no. 2, p. e0297921, 2024.

[4] E. Alfaro, C. Sostres, and A. Lanas, “Diagnosis and treatment of *Helicobacter pylori* infection in real practice—new role of primary care services in antibiotic resistance era,” *Diagnostics*, vol. 13, no. 11, p. 1918, 2023.

[5] M. Allami, M. Bahreini, and M. R. Sharifmoghadam, “Antibiotic resistance, phylogenetic typing, and virulence genes profile analysis of uropathogenic *Escherichia coli*,” *Journal of Applied Genetics*, vol. 63, no. 2, pp. 401–412, 2022.

[6] M. Al-Orphaly *et al.*, “Epidemiology of multidrug-resistant *Pseudomonas aeruginosa* in the Middle East and North Africa Region,” *mSphere*, vol. 6, no. 3, 2021.

[7] M. Alsan *et al.*, “Out-of-pocket health expenditures and antimicrobial resistance in low-income and middle-income countries,” *The Lancet Infectious Diseases*, vol. 15, no. 10, pp. 1203–1210, 2015.

[8] G. Angeles Flores *et al.*, “Advancements in antibacterial therapy: Feature papers,” *Microorganisms*, vol. 13, no. 3, p. 557, 2025.

[9] B. Aslam *et al.*, “Antibiotic resistance: A rundown of a global crisis,” *Infection and Drug Resistance*, pp. 1645–1658, 2018.

[10] S. Baker *et al.*, “Genomic insights into the emergence and spread of antimicrobial-resistant

bacterial pathogens," *Science*, vol. 360, no. 6390, pp. 733–738, 2018.
[11] H. Bao, L. Deng, and Z. Hui, "Unraveling the dynamics of drug resistance: Insights from molecular epidemiology," *Theoretical and Natural Science*, vol. 49, pp. 133–138, 2024.
[12] A. Baran, A. Kwiatkowska, and L. Potocki, "Antibiotics and bacterial resistance—A short story of an endless arms race," *International Journal of Molecular Sciences*, vol. 24, no. 6, p. 5777, 2023.
[13] B. G. Bell *et al.*, "A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance," *BMC Infectious Diseases*, vol. 14, 2014.
[14] M. S. Berends *et al.*, "AMR: An R package for working with antimicrobial resistance data," *Journal of Statistical Software*, vol. 104, pp. 1–31, 2022.
[15] I. Boszczowski *et al.*, "Multidrug-resistant *Klebsiella pneumoniae*: genetic diversity, mechanisms of resistance to polymyxins and clinical outcomes," *Revista do Instituto de Medicina Tropical de São Paulo*, vol. 61, p. e29, 2019.
[16] N. Bourgi, A. Najdi, and G. Hatem, "Predictors of antibiogram performance and antibiotic resistance patterns," *Exploratory Research in Clinical and Social Pharmacy*, vol. 13, p. 100416, 2024.
[17] F. Branda and F. Scarpa, "Implications of artificial intelligence in addressing antimicrobial resistance," *Antibiotics*, vol. 13, no. 6, p. 502, 2024.
[18] L. Bujanda *et al.*, "Antibiotic resistance prevalence and trends in *Helicobacter pylori* (2013–2020)," *Antibiotics*, vol. 10, no. 9, p. 1058, 2021.
[19] S. T. Cardona, A. Z. Rahman, and J. Novomisky Nechcoff, "Innovative perspectives on the discovery of small molecule antibiotics," *npj Antimicrobials and Resistance*, vol. 3, no. 1, p. 19, 2025.
[20] L. Chan, "Global status of antibiotic resistance and management," 2023.
[21] A. S. Chaudhary, "A review of global initiatives to fight antibiotic resistance and recent antibiotics' discovery," *Acta Pharmaceutica Sinica B*, vol. 6, no. 6, pp. 552–556, 2016.
[22] F. Chereau *et al.*, "Risk assessment for antibiotic resistance in South East Asia," *BMJ*, vol. 358, 2017.
[23] L. Chindelevitch *et al.*, "Applying data technologies to combat AMR: current status, challenges, and opportunities," *arXiv preprint arXiv:2208.04683*, 2022.
[24] P. Collignon *et al.*, "Anthropological and socioeconomic factors contributing to global antimicrobial resistance," *The Lancet Planetary Health*, vol. 2, no. 9, pp. e398–e405, 2018.
[25] N. Dagli, M. Haque, and S. Kumar, "Bibliometric insights into antibiotic resistance research," *Cureus*, vol. 16, no. 2, 2024.
[26] S. Dutta *et al.*, "Toward One Health approach linking pathogens and antimicrobial resistance," in *Handbook on Antimicrobial Resistance*, Singapore: Springer, 2023, pp. 303–341.
[27] T. K. Dutta, S. K. Yadav, and A. Chatterjee, "Antibiotics as feed additives for livestock: Human health concerns," *Indian Journal of Animal Health*, vol. 58, no. 2, pp. 121–136, 2019.
[28] S. A. Fonseca-Martínez *et al.*, "Association between *E. coli* virulence genes and antibiotic resistance," *Infection and Drug Resistance*, pp. 3707–3718, 2023.
[29] Q. Fu *et al.*, "From data to action: Charting a data-driven path to combat antimicrobial resistance," *arXiv preprint arXiv:2502.00061*, 2025.
[30] A. K. Garg *et al.*, "Antibiotic prescription pattern among Indian oral healthcare providers," *Journal of Antimicrobial Chemotherapy*, vol. 69, no. 2, pp. 526–528, 2014.
[31] K. Hamdulay *et al.*, "Evolving epidemiology and antibiotic resistance in enteric fever," *Cureus*, vol. 16, no. 6, 2024.
[32] S. Hashemi, A. Nasrollah, and M. Rajabi, "Irrational antibiotic prescribing: A global concern," *EXCLI Journal*, vol. 12, p. 384, 2013.
[33] J. J. Ho *et al.*, "*Helicobacter pylori* antibiotic resistance in the United States," *American Journal of Gastroenterology*, vol. 117, no. 8, pp. 1221–1230, 2022.
[34] H. Jaka *et al.*, "Magnitude of antibiotic resistance in *H. pylori* in Africa," *BMC Infectious Diseases*, vol. 18, 2018.
[35] A. P. Johnson and N. Woodford, "Global spread of antibiotic resistance," *Journal of Medical Microbiology*, vol. 62, no. 4, pp. 499–513, 2013.

[36] M. Kakkar *et al.*, “Antimicrobial resistance in South East Asia,” *Global Health Action*, vol. 11, no. 1, 2018.
[37] A. Karnwal *et al.*, “Addressing bacterial drug resistance,” *Frontiers in Microbiology*, vol. 16, p. 1517772, 2025.
[38] N. J. Khan *et al.*, “Big data in antimicrobial resistance,” in *AI-Driven Breakthroughs*, IGI Global, 2025.
[39] R. T. Khan *et al.*, “Prevention and remedies for antibiotic resistance,” *Frontiers in Microbiology*, vol. 15, 2024.
[40] E. Y. Klein *et al.*, “Tracking global trends in antibiotic effectiveness,” *BMJ Global Health*, vol. 4, no. 2, 2019.
[41] H. Y. Li *et al.*, “Management of ventilator-associated pneumonia,” *Frontiers in Pharmacology*, vol. 13, 2022.
[42] Y. Lin *et al.*, “Antibiotic resistance in *Helicobacter pylori*,” *Journal of Clinical Laboratory Analysis*, vol. 37, no. 7, 2023.
[43] C. Llor and L. Bjerrum, “Antimicrobial resistance and antibiotic overuse,” *Therapeutic Advances in Drug Safety*, vol. 5, no. 6, pp. 229–241, 2014.
[44] Q. Ma *et al.*, “Tailored therapy for *H. pylori* eradication,” *Frontiers in Pharmacology*, vol. 13, 2022.
[45] R. Namusoosa *et al.*, “Epidemiology of antibiotic-resistant pathogens in Uganda,” *Journal of Global Health*, vol. 14, 2024.
[46] R. Oldenkamp *et al.*, “Global prevalence map of antimicrobial resistance,” *PNAS*, vol. 118, no. 1, 2021.
[47] E. N. Ontsira Ngoyi *et al.*, “Detection of *H. pylori* resistance in Congo,” *Helicobacter*, vol. 20, no. 4, pp. 316–320, 2015.
[48] M. Pattnaik *et al.*, “Determinants of antimicrobial misuse,” *Frontiers in Public Health*, vol. 10, 2023.
[49] E. Rahbe *et al.*, “Worldwide antibiotic resistance dynamics,” *medRxiv*, 2022.
[50] J. Salgado *et al.*, “Advancing antibiotic discovery,” *Frontiers in Microbiology*, vol. 16, 2025.
[51] O. Săndulescu *et al.*, “Antibiotic prescribing in dental medicine,” *Tropical Medicine and Infectious Disease*, vol. 9, no. 2, 2024.
[52] A. Savoldi *et al.*, “Prevalence of antibiotic resistance in *H. pylori*,” *Gastroenterology*, vol. 155, no. 5, pp. 1372–1382, 2018.
[53] L. J. Shallcross and D. S. C. Davies, “Antibiotic overuse as driver of resistance,” *British Journal of General Practice*, vol. 64, no. 629, pp. 604–605, 2014.
[54] P. R. Shankar *et al.*, “The state of the world’s antibiotics 2015,” *Journal of Chitwan Medical College*, vol. 6, no. 4, pp. 68–69, 2016.
[55] D. Sharma *et al.*, “Nanotechnology in antimicrobial resistance,” *Frontiers in Microbiology*, vol. 15, 2025.
[56] S. Sharma *et al.*, “Emerging challenges in antimicrobial resistance,” *Frontiers in Microbiology*, vol. 15, 2024.
[57] M. Shatila and A. S. Thomas, “Diagnosis and management of *H. pylori* infection,” *Journal of Clinical Medicine*, vol. 11, no. 17, 2022.
[58] S. Sridhar *et al.*, “Global AMR dynamics through sequencing,” *bioRxiv*, 2025.
[59] K. W. K. Tang, B. C. Millar, and J. E. Moore, “Antimicrobial resistance (AMR),” *British Journal of Biomedical Science*, vol. 80, 2023.
[60] W. Tao *et al.*, “Proxy indicators for antibiotic consumption,” *Bulletin of the World Health Organization*, vol. 97, no. 1, 2019.
[61] J. J. Tiong *et al.*, “Global antimicrobial stewardship challenges,” *Frontiers in Microbiology*, vol. 7, 2016.
[62] P. Tiwari *et al.*, “Antimicrobial peptides in therapeutics,” *Life*, vol. 13, no. 9, 2023.
[63] C. Uruén *et al.*, “How *Streptococcus suis* escapes antibiotics,” *Veterinary Research*, vol. 53, 2022.
[64] T. P. Van Boeckel *et al.*, “Reducing antimicrobial use in food animals,” *Science*, vol. 357, no. 6358, pp. 1350–1352, 2017.

[65] O. Vázquez-Cancela *et al.*, "Assessing antibiotic education among medical students," *Antibiotics*, vol. 13, no. 12, 2024.
[66] N. Woodford, J. F. Turton, and D. M. Livermore, "Multiresistant Gram-negative bacteria," *FEMS Microbiology Reviews*, vol. 35, no. 5, pp. 736–755, 2011.
[67] M. Woolhouse *et al.*, "Global disease burden due to antibiotic resistance," *Journal of Global Health*, vol. 6, no. 1, 2016.
[68] C. Yang, Y. Xiang, and S. Qiu, "Resistance in enteric bacteria," *Current Opinion in Infectious Diseases*, vol. 36, no. 5, pp. 360–365, 2023.
[69] N. Zhou *et al.*, "Global antimicrobial resistance using One Health Index," *Infectious Diseases of Poverty*, vol. 11, no. 1, 2022.
[70] N. Zhou, Z. Cheng, X. Zhang, C. Lv, C. Guo, H. Liu, and Y. Zhu, "Global antimicrobial resistance: A system-wide comprehensive investigation using the Global One Health Index," *Infectious Diseases of Poverty*, vol. 11, no. 1, p. 92, 2022.